Clinical implications of pleural effusions in ovarian cancer

Respirology

Volumn 17, Issue 7, 2012, Pages 1060-1067

  Porcel, José M ^a   Diaz, John P ^b   Chi, Dennis S ^c  

^a HOSPITAL ARNAU DE VILANOVA   (Spain)

^b UNIVERSITY OF MIAMI   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

malignant pleural effusion; ovarian cancer; pleurodesis; thoracoscopy

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; DOCETAXEL; PACLITAXEL;

ADD ON THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CYTOLOGY; CYTOREDUCTIVE SURGERY; DISEASE SEVERITY; EXCISION; FALSE NEGATIVE RESULT; HUMAN; MALIGNANT PLEURA EFFUSION; MALIGNANT PLEURAL EFFUSION; MULTIPLE CYCLE TREATMENT; OVARY CANCER; OVARY CARCINOMA; PLEURA CANCER; PLEURA EFFUSION; PLEURA METASTASIS; PLEURODESIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; VIDEO ASSISTED THORACOSCOPIC SURGERY;

FEMALE; HUMANS; OVARIAN NEOPLASMS; PLEURAL EFFUSION, MALIGNANT; PLEURAL NEOPLASMS; PROGNOSIS; THORACIC SURGERY, VIDEO-ASSISTED;

EID: 84866667034     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2012.02177.x     Document Type: Review

References (55)

1. Jemal A, Bray F, Center MM, et al,. Global cancer statistics. CA Cancer J. Clin. 2011; 61: 69-90.
2. Jelovac D, Armstrong DK,. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J. Clin. 2011; 61: 183-203.
3. Zhang S, Royer R, Li S, et al,. Frequencies of BRCA1 and BRCA2 mutations among 1342 unselected patients with invasive ovarian cancer. Gynecol. Oncol. 2011; 121: 353-7.
4. Berek JS, Chalas E, Edelson M, et al,. Prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancer. Obstet. Gynecol. 2010; 116: 733-43.
5. Tarn AC, Lapworth R,. Biochemical analysis of ascitic (peritoneal) fluid: what should we measure? Ann. Clin. Biochem. 2010; 47: 397-407.
6. Bielsa S, Porcel JM, Castellote J, et al,. Solving the Light's criteria misclassification rate of cardiac and hepatic transudates. Respirology 2012; 17: 721-6.
7. Moore RG, Maclaughlan S,. Current clinical use of biomarkers for epithelial ovarian cancer. Curr. Opin. Oncol. 2010; 22: 492-7.
8. Escudero JM, Auge JM, Filella X, et al,. Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases. Clin. Chem. 2011; 57: 1534-44.
9. Shen-Gunther J, Mannel RS,. Ascites as a predictor of ovarian malignancy. Gynecol. Oncol. 2002; 87: 77-83.
10. Hernández P, Bielsa S, Pardina M, et al,. Meig's syndrome. Int. Pleural Newsl. 2011; 9: 10.
11. Maeda H, Okabayashi T, Hanazaki K, et al,. Clinical experience of pseudo-Meig's syndrome due to colon cancer. World J. Gastroenterol. 2011; 17: 3263-6.
12. Cetin B, Aslan S, Akinci M, et al,. A long survival case of pseudo-Meig's syndrome caused by Krukenberg tumor of the stomach. Jpn J. Clin. Oncol. 2005; 35: 221-3.
13. Kawakubo N, Okido M, Tanaka R, et al,. Pseudo-Meig's syndrome associated with breast cancer metastasis to both ovaries: report of a case. Surg. Today 2010; 40: 1148-51.
14. Al-Agha OM, Nicastri AD,. An in-depth look at Krukenberg tumor: an overview. Arch. Pathol. Lab. Med. 2006; 130: 1725-30.
15. Cellerin L, Marcq M, Sagan C, et al,. Pleurésies malignes révélatrices d'un cancer: comparaison des etiologies avec les pleurésies métastatiques d'un cancer connu. Rev. Mal. Respir. 2008; 25: 1104-9.
16. Wimberger P, Wehling M, Lehmann N, et al,. Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease. Ann. Surg. Oncol. 2010; 17: 1642-8.
17. Bristow R, Amstrong D, (eds). Ovarian Cancer. Saunders Elsevier, Philadelphia, PA, 2010.
18. Terauchi F, Kobayashi I, Nagashima T, et al,. Pilot study on transdiaphragmatic thoracoscopic assisted pleural biopsy and intrathoracic washing cytology for stage IIIc ovarian cancer with diaphragmatic metastases. Int. J. Gynecol. Cancer 2009; 19: 300-3.
19. Fleury AC, Kushnir CL, Giuntoli IIRL, et al,. Upper abdominal cytoreduction and thoracoscopy for advanced epithelial ovarian cancer: unanswered questions and the impact on treatment. BJOG 2012; 119: 202-6.
20. Porcel J, Rodríguez-Panadero F,. Malignant effusions. In:, Maskell N, Millar A, (eds) Oxford Desk Reference: Respiratory Medicine. Oxford University Press, Oxford, 2009; 342-5.
21. Rodríguez-Panadero F,. Medical thoracoscopy. Respiration 2008; 76: 363-72.
22. Ganjei-Azar P, Jordà M, Krishan A, (eds). Effusion Cytology. A Practical Guide to Cancer Diagnosis. Demos Medical, New York, 2011.
23. Westfall DE, Fan X, Marchevsky AN,. Evidence-based guidelines to optimize the selection of antibody panels in cytopathology: pleural effusions with malignant epithelioid cells. Diagn. Cytopathol. 2010; 38: 9-14.
24. Díaz JP, Abu-Rustum NR, Sonoda Y, et al,. Video-assisted thoracic surgery (VATS) evaluation of pleural effusions in patients with newly diagnosed advanced ovarian carcinoma can influence the primary management choice for these patients. Gynecol. Oncol. 2010; 116: 483-8.
25. Kim KW, Choi HJ, Kang S, et al,. The utility of multi-detector computed tomography in the diagnosis of malignant pleural effusion in the patients with ovarian cancer. Eur. J. Radiol. 2010; 75: 230-5.
26. Mironov O, Sala E, Mironov S, et al,. Thoracic metastases in advanced ovarian cancer: comparison between computed tomography and video-assisted thoracic surgery. J. Gynecol. Oncol. 2011; 22: 260-8.
27. Cohen-Mouly S, Badia A, Bats AS, et al,. Role of video-assisted thoracoscopy in patients with ovarian cancer and pleural effusion. Int. J. Gynecol. Cancer 2009; 19: 1662-5.
28. Juretzka MM, Abu-Rustum NR, Sonoda Y, et al,. The impact of video-assisted thoracic surgery (VATS) in patients with suspected advanced ovarian malignancies and pleural effusions. Gynecol. Oncol. 2007; 104: 670-4.
29. Morgan RJ, Alvarez RD, Armstrong DK, et al,. Epithelial ovarian cancer. J. Natl Compr. Canc. Netw. 2011; 9: 82-113.
30. Vergote I, Tropé CG, Amant F, et al,. Neodjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N. Engl. J. Med. 2010; 363: 943-53.
31. Amstrong DK, Bundy B, Wenzel L, et al,. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 2006; 354: 34-43.
32. Chi DS, Eisenhauer EL, Zivanovic O, et al,. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol. Oncol. 2009; 114: 26-31.
33. Rauh-Hain JA, Rodriguez N, Growdon WB, et al,. Primary debulking surgery versus neodjuvant chemotherapy in stage IV ovarian carcinoma. Ann. Surg. Oncol. 2012; 19: 959-65.
34. Gerestein CG, Eijkemans MJ, Bakker J, et al,. Nomogram for suboptimal cytoreduction at primary surgery for advanced stage ovarian cancer. Anticancer Res. 2011; 31: 4043-9.
35. Aletti GD, Eisenhauer EL, Santillan A, et al,. Identification of patient groups at higher risk from traditional approach to ovarian cancer treatment. Gynecol. Oncol. 2011; 120: 23-8.
36. Elattar A, Bryant A, Winter-Roach BA, et al,. Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database Syst. Rev. 2011; (8): CD007565.
37. Bristow RE, Tomacruz RS, Armstrong DK, et al,. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J. Clin. Oncol. 2002; 20: 1248-59.
38. Schorge JO, Garrett LA, Goodman A,. Cytoreductive surgery for advanced ovarian cancer: Quo Vadis? Oncology (Williston Park) 2011; 25: 928-34.
39. Eisenhauer EL, D'Angelica MI, Abu-Rustum NR, et al,. Incidence and management of pleural effusions after diaphragm peritonectomy or resection for advanced mullerian cancer. Gynecol. Oncol. 2006; 103: 871-7.
40. Gouy S, Chereau E, Custodio AS, et al,. Surgical procedures and morbidities of diaphragmatic surgery in patients undergoing initial or interval debulking surgery for advanced-stage ovarian cancer. J. Am. Coll. Surg. 2010; 210: 509-14.
41. Fanfani F, Fagotti A, Gallotta V, et al,. Upper abdominal surgery in advanced and recurrent ovarian cancer: role of diaphragmatic surgery. Gynecol. Oncol. 2010; 116: 497-501.
42. Tsolakidis D, Amant F, Leunen K, et al,. Comparison of diaphragmatic surgery at primary or interval debulking in advanced ovarian carcinoma: an analysis of 163 patients. Eur. J. Cancer 2011; 47: 191-8.
43. Zapardiel I, Peiretti M, Zanagnolo V, et al,. Diaphragmatic surgery during primary cytoreduction for advanced ovarian cancer. Peritoneal stripping versus diaphragmatic resection. Int. J. Gynecol. Cancer 2011; 21: 1698-703.
44. Chéreau E, Rouzier R, Gouy S, et al,. Morbidity of diaphragmatic surgery for advanced ovarian cancer: retrospective study of 148 cases. Eur. J. Surg. Oncol. 2011; 37: 175-80.
45. Aletti GD, Podratz KC, Cliby WA, et al,. Stage IV ovarian cancer: disease site-specific rationale for postoperative treatment. Gynecol. Oncol. 2009; 112: 22-7.
46. Eisenkop SM,. Thoracoscopy for the management of advanced epithelial ovarian cancer-A preliminary report. Gynecol. Oncol. 2002; 84: 315-20.
47. Burger RA, Brady MF, Bookman MA, et al,. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N. Engl. J. Med. 2011; 365: 2473-83.
48. Barbetakis N, Asteriou C, Papadopoulou F, et al,. Early and late morbidity and mortality and life expectancy following thoracoscopic talc insufflation for control of malignant pleural effusions: a review of 400 cases. J. Cardiothorac. Surg. 2010; 5: 27.
49. Whitworth JM, Schneider KE, Fauci JM, et al,. Outcomes of patients with gynecologic malignancies undergoing video-assisted thoracoscopic surgery (VATS) and pleurodesis for malignant pleural effusion. Gynecol. Oncol. 2012 http://dx.doi.org/10.1016/j.ygyno.2012.02.029
50. Bielsa S, Hernández P, Rodriguez-Panadero F, et al,. Tumor type influences the effectiveness of pleurodesis in malignant effusions. Lung 2011; 189: 151-5.
51. Lombardi G, Nicoletto MO, Gusella M, et al,. Intrapleural paclitaxel for malignant pleural effusion from ovarian and breast cancer: a phase II study with pharmacokinetic analysis. Cancer Chemother. Pharmacol. 2012; 69: 781-7.
52. Marom EM, Erasmus JJ, Herndon JE, et al,. Usefulness of imaging-guided catheter drainage and talc sclerotherapy in patients with metastatic gynecologic malignancies and symptomatic pleural effusions. AJR Am. J. Roentgenol. 2002; 179: 105-8.
53. Gross JL, DiSanzio TG, Younes RN, et al,. Do concomitant ascites influence the effectiveness of palliative surgical management of pleural effusions in patients with malignancies? World J. Surg. 2009; 33: 266-71.
54. Eitan R, Levine DA, Abu-Rustum N, et al,. The clinical significance of malignant pleural effusions in patients with optimally debulked ovarian carcinoma. Cancer 2005; 103: 1397-401.
55. Mironov O, Ishill NM, Mironov S, et al,. Pleural effusion detected at CT prior to primary cytoreduction for stage III or IV ovarian carcinoma: effect on survival. Radiology 2011; 258: 776-84.